Never have seen a more mismanaged company in all my years in Investment banking. These three have used this company for their own benefit paying themselves extraordinary quarter million plus salaries for pathetic performance. As an investment banker focused in the diagnostic world, I can attest that this company is being sold for a fraction of what it potential could have been with different management.
These three should not be allowed to control any public company.
Management believes it can be ready by 2016 and drive revenue to fund bryostatin-1 2a trial for Alzheimers. With the discovery that bryostatin-1 activates PKC and that PKC has a central
role in a number of AD-related cellular processes, attention has now turned to testing bryostatin-1 as an AD
therapeutic. Still valued for less than $60M and a diagnostic gem that is not being given any value. Company has enough $ to see it into 2016.